Jeena Sikho Lifecare Limited has announced the grant of 2,18,875 employee stock options to 1,176 eligible employees under its ESOP 2025 scheme. The Nomination and Remuneration Committee of the Board of Directors approved this grant on January 1, 2026, marking a significant step in the company's employee incentivization strategy aimed at employee motivation and long-term value creation.

ESOP Grant Details

The comprehensive employee stock option grant encompasses substantial participation across the organization. The scheme demonstrates the company's commitment to employee motivation and long-term value creation through equity participation.

Regulatory Compliance and Structure

The ESOP 2025 scheme operates in full compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and other applicable laws. Each stock option, upon exercise, will convert into one fully paid-up equity share of face value ₹2.00 each, providing employees with direct ownership stakes in the company.

The exercise period will commence from the date of vesting and expire upon completion of one year from the vesting date. This structure provides employees with a defined timeframe to exercise their options while maintaining alignment with company performance objectives.

Share Rights and Benefits

Shares arising from the conversion of these options will rank pari passu with all other existing equity shares of the company. This ensures that employees exercising their options receive full shareholder rights and benefits equivalent to other equity holders.

The grant represents a strategic initiative to retain talent and align employee interests with long-term company growth. The substantial number of beneficiaries across 1,176 employees indicates broad-based participation in the company's equity growth potential.

Implementation Timeline and Disclosure

The formal disclosure was made pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company has fulfilled all regulatory requirements for the grant announcement, with Managing Director Manish Grover signing the official communication from the company's Zirakpur, Punjab location.

This ESOP grant establishes a foundation for employee engagement through equity participation while maintaining compliance with all applicable securities regulations and disclosure requirements.

Jeena Sikho Lifecare Limited has announced the publication of three new case studies focusing on chronic kidney disease (CKD) management through Ayurvedic interventions. The company filed an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on December 30, 2025, regarding these academic publications.

New Research Publications on Kidney Health

The three studies have been published in the International Journal of Ayurveda and Herbal Research and the Journal of Applied Science and Education. These publications represent a shift in focus from the company's previous research on liver health and diabetes to specialized kidney disease management.

Clinical Outcomes and Patient Improvements

The case studies demonstrate significant improvements in patient outcomes across multiple parameters. The research involved patients with varying stages of CKD, including advanced cases with comorbidities such as hypertension, Type 2 diabetes, and coronary artery disease.

Comprehensive Treatment Approach

The studies showcase integrated treatment protocols combining Ayurvedic medicines, Panchakarma therapies, and lifestyle modifications. The research involved patients aged 50-57 years with varying durations of kidney disease, demonstrating the versatility of Ayurvedic interventions.

Key treatment components included specialized formulations such as Nefron Plus Capsules, CKD Tablets, and Renal Support Capsules, alongside traditional therapies like Basti, Shirodhara, and Abhyanga. The studies also emphasized the importance of dietary modifications and stress management techniques.

Research Team and Methodology

The publications were co-authored by Managing Director Acharya Manish Grover and a team of medical professionals including Dr. Gitika Chaudhary, Dr. Richa, Dr. Shivani Dhiman, Dr. Tanu Rani, Dr. Priyanka Biswas, Dr. Suyash Pratap Singh, and Dr. Shubham Badhan.

The research methodology involved comprehensive patient assessments, including Ashta-Vidh Pariksha (eight-fold examination), regular monitoring of vital parameters, and detailed documentation of treatment responses over extended periods.

Implications for Ayurvedic Medicine

These publications contribute to the growing body of evidence supporting Ayurvedic interventions in chronic disease management. The studies provide detailed documentation of treatment protocols, patient responses, and clinical outcomes, potentially influencing future research directions in integrative nephrology.

The research demonstrates the company's commitment to evidence-based Ayurvedic practice and its role in advancing scientific understanding of traditional medicine applications in modern healthcare settings.